T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018’, provides in depth analysis on T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease, Immunology, Central Nervous System, Cardiovascular and Gastrointestinal under development targeting T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)

- The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects

- The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Evotec AG

Immupharma Plc

TaiMed Biologics Inc

United Biomedical Inc

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Evotec AG

Immupharma Plc

TaiMed Biologics Inc

United Biomedical Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4 ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Evotec AG

Immupharma Plc

TaiMed Biologics Inc

United Biomedical Inc

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles

Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD4 and gp120 for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Target CD4 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

forigerimod acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-48U1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAX-16H5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD4 for HIV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-441236 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate CD4 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMB-360 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMB-365 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tregalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-421 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones

Featured News & Press Releases

Oct 30, 2018: Trogarzo phase III data analysis presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study

Oct 29, 2018: United States Department of Health and Human Services publishes new HIV Treatment guidelines including Trogarzo

Oct 03, 2018: Pharmacokinetic profile of Trogarzo presented at IDWeek

Aug 28, 2018: Theratechnologies files marketing authorization application for Trogarzo in Europe

Aug 15, 2018: New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Aug 15, 2018: the New England Journal of Medicine publishes two articles about Trogarzo

Jul 31, 2018: European Medicines Agency confirms accelerated assessment procedure for Trogarzo

Jul 25, 2018: Trogarzo included in most recent treatment guidelines issued by International Antiviral Society

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

May 29, 2018: Further Analysis from its Pivotal Phase III Trial of Lupuzor in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort

May 23, 2018: Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo

May 16, 2018: Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status

Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.

Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference

Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biotest AG, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by CEL-SCI Corp, H2 2018

Pipeline by Evotec AG, H2 2018

Pipeline by Immupharma Plc, H2 2018

Pipeline by TaiMed Biologics Inc, H2 2018

Pipeline by United Biomedical Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports